Division of Pulmonary and Critical Care Medicine, Interventional Pulmonology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, POB Building II, Dallas, TX, 75390, USA.
Lung. 2019 Oct;197(5):627-633. doi: 10.1007/s00408-019-00268-7. Epub 2019 Aug 28.
Air leaks are common after lobectomy, segmentectomy, and lung volume reduction surgery (LVRS). This can increase post-operative morbidity, cost, and hospital length of stay. The management of post-pulmonary resection air leaks remains challenging. Minimally invasive effective interventions are necessary. The Spiration Valve System (SVS, Olympus/Spiration Inc., Redmond, WA, US) is approved by the FDA under humanitarian use exemption for management of prolonged air leaks.
This is a prospective multicenter registry of 39 patients with air leaks after lobectomy, segmentectomy, and LVRS managed with an intention to use bronchoscopic SVS to resolve air leaks.
Bronchoscopic SVS placement was feasible in 82.1% of patients (32/39 patients) and 90 valves were placed with a median of 2 valves per patient (mean of 2.7 ± 1.5 valves, range of 1 to 7 valves). Positive response to SVS placement was documented in 76.9% of all patients (30/39 patients) and in 93.8% of patients when SVS placement was feasible (30/32 patients). Air leaks ultimately resolved when SVS placement was feasible in 87.5% of patients (28/32 patients), after a median of 2.5 days (mean ± SD of 8.9 ± 12.4 days). Considering all patients with an intention to treat analysis, bronchoscopic SVS procedure likely contributed to resolution of air leaks in 71.8% of patients (28/39 patients). The post-procedure median hospital stay was 4 days (mean 6.0 ± 6.1 days).
This prospective registry adds to the growing body of literature supporting feasible and effective management of air leaks utilizing one-way valves.
肺叶切除术、肺段切除术和肺减容术后常发生空气漏。这会增加术后发病率、成本和住院时间。肺切除术后空气漏的管理仍然具有挑战性。需要微创有效的干预措施。Spiration 阀系统(SVS,Olympus/Spiration Inc.,Redmond,WA,美国)已获得 FDA 的批准,可根据人道主义豁免使用,用于治疗迁延性空气漏。
这是一项针对 39 例肺叶切除术、肺段切除术和 LVRS 术后空气漏患者的前瞻性多中心登记研究,旨在使用支气管镜 SVS 来解决空气漏。
支气管镜 SVS 放置在 82.1%的患者(32/39 例)中是可行的,共放置了 90 个阀门,每个患者中位数放置 2 个阀门(平均 2.7±1.5 个阀门,范围为 1 至 7 个阀门)。所有患者中 76.9%(30/39 例)和可行患者中 93.8%(30/32 例)记录到 SVS 放置的阳性反应。在可行的 32 例患者中,87.5%(28/32 例)的患者最终通过 SVS 放置解决了空气漏,中位时间为 2.5 天(平均 8.9±12.4 天,SD)。在所有意向治疗的患者中,支气管镜 SVS 操作可能有助于 71.8%的患者(39 例中的 28 例)解决空气漏。术后中位住院时间为 4 天(平均 6.0±6.1 天)。
这项前瞻性登记研究增加了越来越多的文献支持使用单向阀对空气漏进行可行和有效的管理。